Metro Healthcare Indonesia Tbk PT
IDX:CARE

Watchlist Manager
Metro Healthcare Indonesia Tbk PT Logo
Metro Healthcare Indonesia Tbk PT
IDX:CARE
Watchlist
Price: 412 IDR -2.37% Market Closed
Market Cap: 13.7T IDR

Intrinsic Value

The intrinsic value of one CARE stock under the Base Case scenario is 11.96 IDR. Compared to the current market price of 412 IDR, Metro Healthcare Indonesia Tbk PT is Overvalued by 97%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CARE Intrinsic Value
11.96 IDR
Overvaluation 97%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Metro Healthcare Indonesia Tbk PT

What is Valuation History?
Ask AI Assistant
What other research platforms think about CARE?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is CARE valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Metro Healthcare Indonesia Tbk PT.

Explain Valuation
Compare CARE to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CARE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Metro Healthcare Indonesia Tbk PT

Current Assets 804.5B
Cash & Short-Term Investments 755.9B
Receivables 36.3B
Other Current Assets 12.4B
Non-Current Assets 3.4T
PP&E 3.4T
Other Non-Current Assets 2.8B
Current Liabilities 617.5B
Accounts Payable 24.4B
Accrued Liabilities 29.1B
Short-Term Debt 516.7B
Other Current Liabilities 47.3B
Non-Current Liabilities 550.4B
Long-Term Debt 541.4B
Other Non-Current Liabilities 9B
Efficiency

Free Cash Flow Analysis
Metro Healthcare Indonesia Tbk PT

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Metro Healthcare Indonesia Tbk PT

Revenue
315.9B IDR
Cost of Revenue
-163.3B IDR
Gross Profit
152.6B IDR
Operating Expenses
-125.9B IDR
Operating Income
26.7B IDR
Other Expenses
-35.3B IDR
Net Income
-8.6B IDR
Fundamental Scores

CARE Profitability Score
Profitability Due Diligence

Metro Healthcare Indonesia Tbk PT's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Operating Margin is Increasing
Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Net Margin is Increasing
42/100
Profitability
Score

Metro Healthcare Indonesia Tbk PT's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

CARE Solvency Score
Solvency Due Diligence

Metro Healthcare Indonesia Tbk PT's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
59/100
Solvency
Score

Metro Healthcare Indonesia Tbk PT's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CARE Price Targets Summary
Metro Healthcare Indonesia Tbk PT

There are no price targets for CARE.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Metro Healthcare Indonesia Tbk PT
does not pay dividends
Shareholder Yield

Current shareholder yield for CARE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one CARE stock?

The intrinsic value of one CARE stock under the Base Case scenario is 11.96 IDR.

Is CARE stock undervalued or overvalued?

Compared to the current market price of 412 IDR, Metro Healthcare Indonesia Tbk PT is Overvalued by 97%.

Back to Top